Clinicopathological characteristics of androgen-dependent advanced prostate cancer patients with α 2-macroglobulin deficiency

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 39-45

  Kanoh, Yuhsaku ^a   Ohtani, Hideki ^a   Egawa, Shin ^b   Baba, Shiro ^a   Akahoshi, Tohru ^a  

^a KITASATO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2 macroglobulin; Androgen dependent advanced prostate cancer; C reactive protein; Interleukin 6; Prostate specific antigen

Indexed keywords

ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALPHA 2 MACROGLOBULIN DEFICIENCY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOELECTROPHORESIS; IMMUNOHISTOCHEMISTRY; LASER NEPHELOMETRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; BONE AND BONES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84862841066     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1437     Document Type: Article

References (27)

1. Ohtani H, Saito M and Koshiba K: Alpha-2-macroglobulin deficiency in patients with advanced prostate cancer. Oncology 42: 341-344, 1985. (Pubitemid 16213235)
2. Kanoh Y, Ohtani H and Koshiba K: Studies on α2-macroglobulin deficiency in association with cancer metastasis. Jpn J Clin Immun 20: 30-43, 1997.
3. Mahour GH, Song MK, Adham NF and Rinderknecht H: Alpha2-macroglobulin deficiency in a patient with Ehlers-Danlos syndrome. Pediatrics 61: 894-897, 1978. (Pubitemid 8338869)
4. Berggvist D and Nilsson IM: Hereditary alpha 2-macroglobulin deficiency. Scand J Haematol 23: 433-436, 1979.
5. Matsuda T, Hirano T, Nagasawa S and Kishimoto T: Identification of α2-macroglobulin as a carrier protein for IL-6. J Immunol 142: 148-152, 1989. (Pubitemid 19034735)
6. Kratzsch J, Selisko T and Birkenmeier G: Identification of transformed α2-macroglobulin as a growth hormone-binding protein in human blood. J Clin Endocrinol Metab 80: 585-590, 1995.
7. Watt KWK, Lee PJ and M'Timkulu T: Human prostate-antigen: structural and similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166-3170, 1986. (Pubitemid 16042997)
8. Smith DS, Humphrey PA and Catalona WJ: The early detection of prostate carcinoma with rostate specific antigen. Cancer 80: 1852-1856, 1997.
9. Stege R, Grande M and Carlstrom K: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Can Res 6: 160-165, 2000. (Pubitemid 30064989)
10. D'Amico AV, Whittington R and Malkowicz SB: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18: 1164-1172, 2000. (Pubitemid 30159832)
11. Kanoh Y, Ohtani N, Ohara T, Mashiko T, Ohtani S, Egawa S Baba S and Ohtani H: Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, α2-macroglobulin, and their complexes. Oncol Rep 8: 515-519, 2001. (Pubitemid 33758446)
12. dos Anjos BL and Grotto HZ: Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious disease in children. Clin Chem Lab Med 48: 493-499, 2010.
13. Kanoh Y, Ohara T and Akahoshi T: Acute inflammatory biomarkers in cerebrospinal fluid as indicator of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitis. Clin Lab 57: 37-46, 2011.
14. Fujiwara H, Suchi K, Okamura H, Umehara S, Toda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T and Otsuji E: Elevated serum CRP levels after indication chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 103: 62-68, 2011.
15. Yap SH, Moshage HJ, Hazenberg BP, Roelofs MH, Bijizet J, Limburg PC, Aarden LA and van Rijiswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1091: 405-408, 1991.
16. Smith JW and McDonald TL: Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol 90: 293-299, 1992.
17. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 39: 1533-1558, 2011.
18. Spiessl B, Beahrs OH and Hermanek P, et al (eds): International Union Against Cancer. TNM Atras. 3rd edition. 2nd revision. Springer-Verlag, New York, NY, pp241-250, 1992.
19. Ida N, Sakurai S, Hosaka T, Hosoi K, Matsuura Y and Kohase M: An enzymelinked immunosorbent assay for the measurement of human interleukin-6. J Immunol Methods 133: 279-284, 1990. (Pubitemid 20338905)
20. Laemmli KU: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
21. Wada C, Kasai K, Kameya T and Ohtani H: A general transcription inhibitor factor, human transcription factor IID, overexpressed in human lung and breast carcinoma and rapidly induced with serum stimulation. Cancer Res 52: 307-313, 1992.
22. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Change of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Clin Lab (In press)
23. Ohlsson K and Laurell CB: The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med 51: 87-92, 1976.
24. Birkenmeier G, Struck F and Gebhardt R: Clearance mechanism of prostate specific antigen and its complexes with α2-macroglobulin and α2-antichymotrypsin. J Urol 162: 897-901, 1999. (Pubitemid 29436913)
25. Labrie F: Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol 198: 77-87, 2002.
26. Siddique HR, Mishra SK, Karnes RJ and Saleem M: Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res 17: 5379-5391, 2011.
27. Salem M and Garcia JA: Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr Oncol Rep 13: 92-96, 2011.